At the clinical stage of the firm's product development, Bacchus Therapeutics is a biotech company developing small molecule inhibitors of cancer metabolic pathways - novel compounds designed to exploit cancer's hypermetabolic state by targeting cancer-specific metabolic pathways. Anchored in the core concept of starving cancer cells of their need for eat and tto make fat (lipids), the firm's proprietary compounds cause regression of incurable MYC cancers and prolong survival in the firm's preclinical mouse models bearing human tumors. With a particular focus cancers caused by the MYC oncogene - responsible for 70% of human cancers - the firm's early efforts had been supported by the entrepreneurship program of SPARK at Stanford, by MBC BioLabs and AbbVie Inc. .In response to available resources. the firm - more recently - also relocated from San Francisco to the east coast and the Prince William Science Accelerator in Virginia
